Sales increase comparison with ResmedResmed reported on Thursday Oct 28. Here is what they said regarding sales increase in their North and South American core business in their most recent quarter:
"Revenue in the U.S., Canada, and Latin America, excluding Software as a Service, grew by 22 percent, primarily due to the factors discussed above and recovery of core sleep patient flow that was previously impacted by COVID-19. Excluding the prior year impact of incremental respiratory care revenue associated with COVID-19, revenue increased by 28 percent."
Viemed core business in Q3 2020 was reported as follows:
"The Company's core business has once again contributed to a significant growth rate. Net revenues attributable to the Company's core business for the quarter ended September 30, 2020 were $24.9 million, an increase of 22% over net revenues reported for the comparable quarter ended September 30, 2019. Net revenues attributable to the core business for the quarter ended September 30, 2020 were up approximately 8% over the quarter ended June 30, 2020."
If Viemed were to achieve a similar 28% increase in core business revenue (similar to Resmed) it would be $31.84 million. However, Viemed guided 2021 Q3 core business revenue of approximately $26.8 million to $27.8 million. This would be a 7.6% to 11.6% increase for Viemed.
Resmed has a P/E of 77.9 while VMD has a P/E of 21.5.
Viemed reports after markets close today.